MedTrace Logo

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

NCT02074982 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 676

Last updated 2017-07-21

Study results available
· View outcomes & findings →

Summary

This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis

Conditions

  • Chronic Plaque Type Psoriasis

Interventions

DRUG

AIN457 300 mg

DRUG

ustekinumab 45/90 mg

DRUG

placebo secukinumab

Placebo

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-26
Primary Completion
2016-06-29
Completion
2016-06-29
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Bulgaria
  • Canada
  • Denmark
  • Estonia
  • France
  • Germany
  • Greece
  • Hungary
  • Israel
  • Italy
  • Netherlands
  • Norway
  • Portugal
  • Slovakia
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02074982 on ClinicalTrials.gov